Abstract:
Background and objective
Methotrexate is the anchor disease-modifying anti-rheumatic drug for rheumatoid arthritis, but
elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) require clinical
review and monitoring. This study determined the occurrence of deranged liver enzymes and associated
factors among methotrexate-treated patients with rheumatoid arthritis.
Methods
A hospital-based descriptive cross-sectional study was conducted among 221 adults receiving
methotrexate for at least six months at the Rheumatology Clinic, Teaching Hospital, Jaffna. Data were
collected using an interviewer-administered questionnaire and a clinical-record extraction form.
Deranged liver enzymes were defined as ALT or AST exceeding 1.5 times the upper limit of normal in
any of the three most recent consecutive reports available at the time of data collection. Categorical and
continuous variables were analyzed using the Chi-square/Fisher's exact test and Mann–Whitney U test,
respectively, with p<0.05 indicating statistical significance.
Results
Deranged liver enzymes were identified in 20 participants (9.0%). Participants were predominantly
female (85.5%); median age was 57 years (IQR 48–65), median weekly methotrexate dose was 10 mg
(IQR 7.5–12.5), and median treatment duration was 5 years (IQR 2–7). Oral traditional medicine use
was associated with deranged liver enzymes (21.7% among users versus 7.6% among non-users;
p=0.042). Age, sex, alcohol use, concomitant anti-rheumatic therapy, methotrexate dose and treatment
duration were not significantly associated.
Conclusions
Approximately one in eleven methotrexate-treated patients had deranged liver enzymes. Concomitant
traditional medicine use was the only identified associated factor. Medication reconciliation and
evaluation of alternative causes should accompany routine transaminase monitoring; causation cannot
be inferred from this cross-sectional study.